Normal
6th - 7th October 2022

4th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference UK/EU

London, UK
150+
Attendees
20+
Speakers
10
Networking Hours
5+
Sessions

Leveraging next gen technologies beyond conventional biomarker drug discovery

The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.

users

20+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Challenges in NGS based CDx and the Importance of imaging biomarkers for precision medicine.

users

Opportunity to develop long-lasting business relationships and networking opportunities with senior peers. Get the Opportunity to get your queries handled by Biomarker experts in one on one session.

users

Facilitated networking sessions to ensure quality interactions along with Case studies from experts who have successfully created and developed a biomarker

The 4th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 6th - 7th October 2022 in London, UK would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers.

This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.

WHAT TO EXPECT

Key Highlights

  • Clinical biomarker identification and qualification 
  • Biomarkers and personalized medicine 
  • Assay development and validation
  • NGS and novel technologies in biomarker discovery
  • Commercialization of biomarkers in therapeutic and CDx applications

Who Should Attend

  • Researchers, scientists, clinicians, academicians and professionals From Pharmaceutical companies, Bio-pharma companies, Universities and Research Institutes.

Departments:

  • Biomarker discovery/development | Translational research | Clinical Biomarker | Biomarkers in IO and Neurological disorders

CONFERENCE AGENDA
CONFERENCE SPEAKERS
Speakers
Jenny Barnett
Jenny Barnett
CEO, Monument Therapeutics
Anita Grigoriadis
Anita Grigoriadis
Reader in Cancer Bioinformatics, King’s College London
Dr. Ian Pike
Dr. Ian Pike
Chief Scientific Officer, Proteome Sciences PLC
Andrew Pierce
Andrew Pierce
Vice President, Translational Biology, Crescendo Biologics
Huw Davies
Huw Davies
VP, Global Sales, Owlstone Medical
Nagy Habib
Nagy Habib
CMO, MiNA Therapeutics
Batika Rana
Batika Rana
Senior Scientist, Orchard Therapeutics
SPONSORS
Gold
example-image

Proteome Sciences

example-image

Owlstone Medical

Silver
example-image

Bcell Design

example-image

Inoviem Scientific

Sponsors & Exhibitors
example-image

Firalis

example-image

Quanterix

example-image

Biognosys

Speaking Partner
example-image

Fastbase Solutions

PARTNERS
Media Partners
example-image

Bentham Science

LOCATION
London, UK
About the Hotel

PAST EVENT GALLERY